Clinical trials: Obese Subjects
Obesity, Cardiovascular Diseases
Naltrexone/Bupropion Cardiovascular Outcomes Study
The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse…
- Trial name
- NCT02638129
- Testing
- Naltrexone HCl/Bupropion HCl ER
- Where
- 139 sites in United States
- Volunteers
- 67 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
- Trial name
- NCT04478708
- Testing
- maridebart cafraglutide
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Amgen
Overweight, Obesity
A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.
The purpose of this study is to determine how VI-0521 affect speed and reaction time on specific tasks that require eye and hand coordination, compared to placebo.
- Trial name
- NCT00806260
- Testing
- VI-0521, Alcohol
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
NAFLD
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
- Trial name
- NCT03744182
- Testing
- HM15211
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non-Alcoholic Steatohepatitis
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.
- Trial name
- NCT02287779
- Testing
- SHP626
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Type 2 Diabetes, Hypertension
Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Insulin resistance has been implicated as the central pathogenetic feature of cardiovascular risk factor cluster that includes hypertension, impaired glucose tolerance, diabetes, dyslipidemia, and hemostatic disorders.
- Trial name
- NCT00738023
- Testing
- Rosiglitazone, Normal saline 0.9%, Intralipid 20%
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Emory University
Liver Diseases
Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to see how effective the investigators' optimized magnetic resonance spectroscopy (MRS) sequence in quantifying hepatic triglyceride content (HTGC) to enhance MRS as a diagnostic tool in non-alcohol…
- Trial name
- NAFLD (NCT00940537)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Type 2 Diabetes Mellitus
Effect on Weight Loss of Exenatide Versus Placebo
This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss. This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with…
- Trial name
- NCT00375492
- Testing
- exenatide
- Where
- 10 sites in United States
- Volunteers
- 196 people
- Sponsor
- AstraZeneca
Obesity
LOSS- Louisiana Obese Subjects Study
LOSS is a pragmatic clinical evaluation of intensive medical approaches to weight loss for individuals with extreme obesity (body mass index [BMI] 40-60 kg/m2).
- Trial name
- LOSS (NCT00115063)
- Testing
- group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- Pennington Biomedical Research Center
Healthy
Pharmacokinetics of Voriconazole in Obese Subjects
Obese subjects may require a higher fixed oral maintenance dosing regimen of voriconazole compared to normal weight subjects to achieve comparable plasma exposures. The current study is designed to address this issue.
- Trial name
- NCT01030653
- Testing
- Voriconazole low dose, Voriconazole high dose
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Manjunath Prakash Pai
Obesity and Diabetes Mellitus, Type 2
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from…
- Trial name
- NCT03586830
- Testing
- JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3
- Where
- 27 sites in United States
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
Exeantide in Type 2 Diabetes on Insulin
Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better…
- Trial name
- NCT01154933
- Testing
- exenatide 5 mcg, exenatide 10 mcg
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University at Buffalo
Obese With Comorbidities, Overweight With Comorbidities
Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities
The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.
- Conditions
- Obese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes
- Trial name
- NCT04167553
- Testing
- HM15136
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus, Type II, Obesity
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus
An exploratory study to evaluate the effect of MEDI0382 on energy balance in overweight and obese participants with type 2 diabetes mellitus
- Trial name
- NCT03596177
- Testing
- MEDI0382
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- MedImmune LLC
Hypogonadotropic Hypogonadism
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism. All subjects will be treated for a maximum of 24 weeks.
- Trial name
- NCT02730169
- Testing
- BGS649
- Where
- 63 sites in United States, Italy and 2 more
- Volunteers
- 271 people
- Sponsor
- Mereo BioPharma
Obesity
A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects
When humans eat, the bowels naturally secrete chemicals into the bloodstream which make people feel full and which stop eating. One of these chemicals is known as "Pancreatic Polypeptide" (PP).
- Trial name
- NCT01052493
- Testing
- PP 1420
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Diabetes, Hypertension
FFA Hypertension and Inflammation in Lean and Obese Subjects
Although a large number of obese patients develop high blood pressure, the cause is unknown. The purpose of this study is to look at the effect of high fatty acids (a type of fat) in the development of high blood pressure in…
- Conditions
- Diabetes, Hypertension, Obesity
- Trial name
- FFAADA (NCT00721617)
- Testing
- Intralipid 20%, Normal Saline, Oral fat load
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Emory University
Heart Failure, Obesity
Fatty Acid Radiotracer Comparison Study in Heart Failure Patients
A single center, open-label baseline controlled imaging study to designed to assess whether Positron Emission Tomography (PET) measurements of myocardial Fatty Acid (FA) metabolism performed with [18F]FluorbetaOx correlates with…
- Conditions
- Heart Failure, Obesity, Type 2 Diabetes Mellitus, Health Normal Volunteer Subjects
- Trial name
- NCT01648296
- Testing
- [18F]FluorbetaOx
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Obesity
Study of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner
The purpose of this study is to determine whether the GI Endobarrier Liner can be reimplanted.
- Trial name
- NCT01372501
- Testing
- Endobarrier Liner
- Where
- Chile
- Volunteers
- 19 people
- Sponsor
- Morphic Medical Inc.
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC